The Latest Cardiac and Vascular News
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and development activities. Further to the Company’s press release dated November 8, 2018 where it discussed research and development initiatives and […]
CALGARY, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its manufacturing process, which will result in an approximate 40% reduction in manufacturing time for its lead product ACP-01. As disclosed […]
CALGARY, Alberta, Oct. 30, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce the Company has been approved for up-listing its common shares for trading on the OTCQB Venture Market, a US trading platform that is operated by the OTC […]
CALGARY, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from three new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb ischemia (“CLI”). In […]
CALGARY, Alberta, Sept. 27, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that at the Annual and Special Meeting of Shareholders (the “Meeting”) held on September 26, 2018, shareholders overwhelmingly approved all the resolutions placed before the Meeting and as outlined […]
CALGARY, Alberta, July 18, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has treated three additional patients including its first two patients in the United States under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”). The first […]
